YM 796

Drug Profile

YM 796

Latest Information Update: 30 Jun 2000

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Yamanouchi
  • Class Neuroprotectants; Nootropics
  • Mechanism of Action Muscarinic M1 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Alzheimer's disease; Dementia

Most Recent Events

  • 30 Jun 2000 Discontinued-I for Alzheimer's disease in Germany (PO)
  • 30 Jun 2000 Discontinued-II for Dementia in Japan (PO)
  • 24 Sep 1998 Phase-II clinical trials for Dementia in Japan (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top